Drug discovery

Exogene is a biotechnology company accelerating the discovery of T-cell-receptor (TCR)- based cancer immunotherapies for solid tumours by combining deep learning and high-throughput TCR-antigen screening. Their mission is to develop better TCR-based cancer immunotherapies, faster and at a fraction of the cost.

Focus: Drug discovery platform 

Team: Federio Paoletti (CEO) and Andrea Mambrini (CTO)

Website: https://exogene.co.uk/ 

We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.